Pembrolizumab as First-line Treatment for Advanced NSCLC Complicated With COPD
NCT05578222
·
clinicaltrials.gov ↗
PHASE2
Phase
UNKNOWN
Status
30
Enrollment
OTHER
Sponsor class
Conditions
NSCLC With COPD
Interventions
DRUG:
Pembrolizumab
Sponsor
Tianjin Chest Hospital